A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910